SAVA 29.62 Cassava Sciences, Inc.
| Range: | 8.79-42.2 | Vol Avg: | 3143698 | Last Div: | 0 | Changes: | 0.94 |
| Beta: | -0.63 | Cap: | 1.24B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jul 14 2000 | Empoloyees: | 29 | ||
| CUSIP: | 14817C107 | CIK: | 0001069530 | ISIN: | US14817C1071 | Country: | US |
| CEO: | Mr. Richard Jon Barry | Website: | https://www.cassavasciences.com | ||||
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Stock Details
Positive 0.44
Why Cassava Sciences Stock Dived by Almost 11% Today
The biotech is paying $40 million not to acquire a drug or fund a development program, but...
fool.com·Fri Sep 27 2024
Neutral -0.06
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims
Cassava Sciences (SAVA) shares dropped more than 11% after the company agreed to a $40 mil...
investopedia.com·Fri Sep 27 2024
Negative -0.23
Cassava Sciences settles SEC charges of ‘misleading' Alzheimer's trial claims
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday aft...
marketwatch.com·Thu Sep 26 2024
Negative -0.14
Cassava Sciences Resolves SEC Investigation
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the...
globenewswire.com·Thu Sep 26 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow